Product Quantum (Rs. Cr) Long Term Rating Short Term Rating
Bank Loan Ratings 45.00 ACUITE BB+ | Stable | Assigned -
Bank Loan Ratings 330.00 ACUITE BB+ | Stable | Upgraded -
Total Outstanding 375.00 - -
Total Withdrawn 0.00 - -
 
Rating Rationale

­Acuité has upgraded its long-term rating to ‘ACUITE BB+’ (read as ACUITE Double B Plus) from ‘ACUITE BB-’ (read as ACUITE Double B Minus) on Rs. 330.00 Cr. bank facilities of Yashoda Foundations (YF). The outlook is ‘Stable’.
Acuité has also assigned its long-term rating of ‘ACUITE BB+’ (read as ACUITE Double B Plus) on the Rs.45.00 crore bank facilities of Yashoda Foundations (YF). The outlook is ‘Stable’.

Rationale for Upgrade
The rating upgrade reflects the successful completion and commencement of operations at Yashoda Medicity in October 2025, marking a transition from project execution to a revenue generating phase and reducing associated business and execution risks. It is also supported by group’s improved operating performance, the promoters’ extensive industry experience, and the group’s established track record, supported by a moderate financial risk profile characterized by healthy net worth, moderate gearing, and comfortable debt-protection metrics. Liquidity is expected to remain adequate, backed by existing arrangements with Yashoda Super Speciality Hospitals Private Limited (YSSHPL) and sufficient cash accruals to meet debt obligations at a group level, although the group’s moderately intensive working-capital requirements continue to constrain the rating. YF also has financial flexibility of the group to repay its debt obligations over the medium term and the renewed sanction letter along with lender stipulations on debt servicing and cash-flow fungibility between the entities remaining key monitorables, including any material changes in the revised terms.


About the Company

­M/s Yashoda Foundations is a trust, incorporated on 2nd September, 1999 at Ghaziabad and established a 635 bed Super Speciality Medical Centre in the name of Yashoda Medicity at Shakti Khand II, Indirapuram, Ghaziabad. The trust was founded by Dr. P.N. Arora. 

 
About the Group

­Yashoda Super Speciality Hospitals Private Limited is a private healthcare company incorporated on 29 December 2019, headquartered at H-1, Kaushambi, Ghaziabad, Uttar Pradesh and runs a 300 bedded hospital at the location. The hospital is known for offering a wide range of super-speciality healthcare services, such as cardiology, neurology, oncology, gastroenterology, nephrology, orthopedics, mother-and-childcare, and critical care. The hospital is equipped with advanced ICUs, modular operation theatres, diagnostic centres, 24/7 emergency and trauma care, and comprehensive lab and imaging services. The hospital’s governance is led by Upasana Arora and Prem Narayan Arora. 

 
Unsupported Rating
­Not Applicable
 
Analytical Approach

Extent of Consolidation
•Full Consolidation
Rationale for Consolidation or Parent / Group / Govt. Support

­Acuite has consolidated the business and financial risk profile of Yashoda Foundations (YF) and Yashoda Super Speciality Hospitals Private Limited (YSSHPL), given the significant operational and financial fungibilities between the two entities. Both the entities have common line of business, common management, and operational as well as financial linkages. Furthermore, YSSHPL is expected to extend a corporate guarantee to YF’s bank facilities.

Key Rating Drivers

Strengths

­Experienced Management
Yashoda Foundation (YF) is a trust which was incorporated on 2nd September 1999 under the leadership of Mr. Prem Narayan Arora, Upasana Arora and other trustees, who are specialized doctors and have long standing experience of running hospitals and medical units. Apart from this, management runs a hospital under the name of Yashoda Super Speciality Hospitals Private Limited (YSSHPL), Kaushambi unit. The vast experience of the trustees in efficiently managing the hospitals has helped them to maintain healthy relations with reputed client like Aarogya PRP Health Care Services, Aditya Birla Health Insurance Company Limited, AIR India, BHEL and others.

Consolidated Revenue Growth with improving Profitability
The revenue of the group stood at Rs.335.27 Cr. in FY2025 as against Rs.261.35 Cr. in FY2024. The improvement in revenue is on the account of increase in average revenue per operating bed (ARPOB) in Yashoda Super Speciality Hospitals Private Limited (YSSHPL), however the overall occupancy has declined marginally. Also, Operations at Yashoda Medicity started recently in October 2025, and going forward it will support revenue growth. As of January 2026, the Yashoda Medicity has achieved around Rs.50 Cr. The operating profit margin of the group improved and stood at 35.22 per cent in FY2025 as against 24.45 per cent in FY2024. The reason for improvement in the operating margin is on the account of increase in ARPOB and increase in number of OPD patients in YSSHPL. The PAT margin also improved and stood at 27.58 per cent in FY2025 as against 18.42 per cent in FY2024. 

Moderate Financial Risk Profile:
The group’s financial risk profile remains moderate, characterized by moderate gearing, healthy networth and debt protection indicators. The net worth of the group improved to Rs. 383.32 crore as on March 31, 2025, compared to Rs. 290.86 crore as on March 31, 2024, due to accretion of profit to reserves. The Gearing (debt-equity) of the group stood at 1.37 times as on March 31, 2025, against 0.92 times in the previous year. The total debt of the group stood at Rs. 526.24 Cr. as on March 31, 2025, as against Rs. 268.67 Cr. as on March 31, 2024. The debt profile of the group comprises of Rs. 412.80 Cr. of long-term debt, Rs. 70.61 Cr. of short-term debt, Rs.37.04 Cr of unsecured loans from promoters and Rs. 5.80 Cr. of current portion of long-term debt. The Total Outside Liabilities/Tangible Net Worth (TOL/TNW) of the group stood at 1.58 times as on March 31, 2025, as against 1.01 times as on March 31,2024. Further, the debt protection metrics of the group stood comfortable as reflected by debt service coverage ratio of 20.11 times for FY2025 as against 40.07 times for FY2024 and the interest coverage ratio stood at 33.74 times for FY2025 as against 45.51 times for FY2024. The net cash accruals to total debt (NCA/TD) stood at 0.20 times in FY2025 as compared to 0.23 times in the previous year.


Weaknesses

­Intensive working capital operations:
The working capital operations of the group remains intensive in nature, marked by high Gross Current Assets (GCA) of 139 days in FY2025, compared to 130 days in FY2024. The high GCA days are on account of high other Current Assets in the form of advance recoverable. The debtor days stood at 38 days in FY2025 as against 36 days in FY2024. Further, the creditor days stood high at 121 days in FY2025 as against 58 days in FY2024. However, the inventory period stood comfortable at 9 days on March 31, 2025, as against 6 days as on March 31, 2024.

Risk associated with regulatory framework in healthcare sector
The healthcare sector functions under multiples layers of regulations of government and professional bodies. In view of the Covid-19 pandemic, regulatory restrictions and state intervention in the normal operations of hospitals has increased. Additionally, the hospital faces intense competition from several players in the city from small players as well as large players.

ESG Factors Relevant for Rating

­Yashoda Foundation serves as the social impact and CSR arm of Yashoda Hospitals, focusing on healthcare access, employability training for orphaned and underprivileged youth, and community-based public health initiatives such as vaccination drives and health camps. The Foundation reflects the Yashoda Group’s broader commitment to socially responsible healthcare delivery and operates within a structured governance and CSR framework. In addition to its core healthcare and skilling initiatives, the Foundation’s sustained engagement with vulnerable communities demonstrates a long-term commitment to inclusive development and improved public health outcomes, reinforcing its strategic relevance under the social pillar of ESG considerations.

 
Rating Sensitivities
  • Substantial improvement in revenue and profitability
  • Improvement in working capital cycle
  • Any material changes in revised sanction letter of YF
  • Timely debt servicing by YF
 
Liquidity Position
Adequate

The group’s liquidity position is adequate, marked by sufficient net cash accruals of Rs. 106.80 Cr. in FY2025 as against maturing debt obligations of Rs.1.82 Cr. in the same tenure. In addition, the group is expected to generate cash accrual in the range of Rs. 100.00 Cr. to Rs.140.00 Cr. as against maturing repayment obligations in the range of Rs. 60-70 Cr over the medium term. On a standalone basis, Yashoda Foundations is expected to generate insufficient net cash accruals for debt servicing and is expected to repay debt obligations from the group’s financial flexibility in initial phases of operation. YSSHPL by virtue of the agreement have already brought in Rs. 167.00 Cr as interest free security deposit in YF and is expected to infuse another RS. 33.00 Cr by FY2026. The cash and bank balances of the group stood at Rs. 9.25 Cr as on March 31, 2025. The current ratio stood at 0.86 times as on March 31, 2025, as compared to 1.83 times as on March 31, 2024.

 
Outlook: Stable
­
 
Other Factors affecting Rating
­None
 

Particulars Unit FY 25 (Actual) FY 24 (Actual)
Operating Income Rs. Cr. 335.27 261.35
PAT Rs. Cr. 92.46 48.14
PAT Margin (%) 27.58 18.42
Total Debt/Tangible Net Worth Times 1.37 0.92
PBDIT/Interest Times 33.74 45.51
Status of non-cooperation with previous CRA (if applicable)
­Not Applicable
 
Any Other Information
­None
 
Applicable Criteria
• Application Of Financial Ratios And Adjustments: https://www.acuite.in/view-rating-criteria-53.htm
• Consolidation Of Companies: https://www.acuite.in/view-rating-criteria-60.htm
• Default Recognition: https://www.acuite.in/view-rating-criteria-52.htm
• Service Sector: https://www.acuite.in/view-rating-criteria-50.htm

Note on complexity levels of the rated instrument

Date Name of Instruments/Facilities Term Amount (Rs. Cr) Rating/Outlook
12 Mar 2025 Term Loan Long Term 330.00 ACUITE BB- | Stable (Reaffirmed)
13 Dec 2023 Term Loan Long Term 330.00 ACUITE BB- | Stable (Assigned)
­

Lender’s Name ISIN Facilities Date Of Issuance Coupon Rate Maturity Date Quantum
(Rs. Cr.)
Complexity Level Rating
Punjab National Bank Not avl. / Not appl. Term Loan 23 Nov 2022 Not avl. / Not appl. 31 Mar 2034 330.00 Simple ACUITE BB+ | Stable | Upgraded ( from ACUITE BB- )
Punjab National Bank Not avl. / Not appl. Term Loan 29 Mar 2025 Not avl. / Not appl. 31 Mar 2034 45.00 Simple ACUITE BB+ | Stable | Assigned


*Annexure 2 - List of Entities (applicable for Consolidation or Parent / Group / Govt. Support)

­
Sr.No. Company Name
1 Yashoda Foundations 
2 Yashoda Super Speciality Hospitals Private Limited
 

Contacts

About Acuité Ratings & Research

© Acuité Ratings & Research Limited. All Rights Reserved.www.acuite.in